William Aliski

Filings by William Aliski span 3 companies, the busiest being Ultragenyx Pharmaceutical Inc., Applied Genetic Technologies Corp and X4 Pharmaceuticals, Inc. The record holds 34 filings, for trades running from 5 February 2014 to 10 June 2024.

The open-market side counts 3 purchases for €17k alongside 14 sales for €5.6M. On balance, insiders were net sellers of €5.6M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 9 share grants and 5 option exercises.

Half of the purchases are above €3,421 and half below. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 11 June 2024 came the latest disclosure, a share grant in X4 Pharmaceuticals, Inc. The clock since the last published purchase (18 December 2018) now reads 2,866 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.